Polymyalgia Rheumatica
3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CP
Chugai PharmaJapan - Tokyo
2 programs1
1
TocilizumabPhase 3Monoclonal Antibody1 trial
TCZPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chugai PharmaTocilizumab
Chugai PharmaTCZ
Clinical Trials (2)
Total enrollment: 134 patients across 2 trials
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Start: Feb 2017Est. completion: Nov 2020113 patients
Phase 3Completed
Tocilizumab Effect iN pOlymyalgia Rheumatica
Start: Jul 2012Est. completion: Oct 201421 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space